Recruitment for a global phase 3 trial is now underway to assess the potential of the SGLT2 inhibitor dapagliflozin as a treatment to reduce COVID-19 progression, complications and death among adults with cardiovascular, metabolic or renal risk factors, according to a press release from AstraZeneca and Saint Luke’s Mid America Heart Institute.
The goal of the trial, called DARE-19, is to assess whether dapagliflozin (Farxiga) could become a treatment option for adults with COVID-19 who are at risk for developing serious complications, such as organ failure. The trial design is supported by extensive data on the protective effect of dapagliflozin among adults with heart failure with reduced ejection fraction (HFrEF), chronic kidney disease or type 2 diabetes.
Dr. Mikhail Kosiborod, principal investigator for DARE-19 and cardiologist at Saint Luke's Mid America Heart Institute, talked to Healio about the new trial.
Read the full Healio: Endocrine Today article: Clinical trial investigates dapagliflozin for COVID-19 treatment